What complications can it help catch?
IRIS, CLARIS, and MERIS are three clinical applications built on one shared physiological platform — each reading the same multimodal signals for a different pattern of postoperative risk.
Three applications. One physiological platform.
Crely doesn't run three separate devices. IRIS, CLARIS, and MERIS interpret the same continuous, multimodal signal stream — each tuned to a different pattern of postoperative risk, and each grounded in physiology rather than a generic score.
Three risks, read from one signal.
Each application is described by the problem it addresses, why that problem is recognized late today, the physiological pattern it reads, and how it fits the care team's workflow. Performance figures are held on the Evidence page, always with their study context.
IRIS
Infection Risk Intelligence SystemSurfaces the physiological signature of an evolving infection — before clinical confirmation.
Postoperative infection often declares itself late — after fever, rising white cells, or a positive culture, by which point the process is already established.
Culture turnaround and overt clinical signs can lag the underlying physiology by many hours to days.
Coordinated shifts across tissue oxygenation, bioimpedance, skin temperature, and autonomic (ECG-derived) markers form a pattern consistent with an evolving infective response.
Contributes an infection-risk signal to the tiered-alert stream, prompting earlier clinical assessment and, where warranted, earlier work-up.
CLARIS
Critical Care Alert & Risk Intelligence SystemFlags acute physiologic deterioration as it develops — ahead of escalation.
Acute metabolic and haemodynamic deterioration — such as rising lactate or acid-base disturbance — can develop quickly between scheduled labs and observations.
Intermittent blood gases and spot vitals can miss the window in which deterioration accelerates.
Continuous multimodal patterns track perfusion and metabolic stress, flagging divergence from the patient's own baseline.
Raises an early deterioration signal so the team can confirm with labs and escalate care sooner.
MERIS
Mortality Event Risk Intelligence SystemIdentifies patients on a persistently high-risk recovery trajectory.
Some patients deteriorate along a slow, sustained trajectory that is hard to see in point-in-time snapshots.
Day-to-day assessments may not reveal a persistent downward trend until late in the course.
Longitudinal analysis of multimodal signals identifies persistently abnormal trajectories rather than isolated events.
Highlights persistently high-risk patients for closer review and multidisciplinary attention.
One platform, room to grow — responsibly.
The same multimodal platform is designed to support additional applications as evidence is established. We describe only what has been developed, and we separate development status from clinical validation at every step — no application is presented as more mature than the evidence supports.
Shared foundation
New applications draw on the same sensing, connectivity, and baseline infrastructure — not a new device each time.
Evidence-gated
An application advances only as its supporting evidence advances — development, then prospective validation.
Status always distinguished
Investigational, in-development, and validated capabilities are labelled distinctly — never blurred together.
See the evidence behind each application.
Cohorts, warning-time, and performance for IRIS, CLARIS, and MERIS — always presented with population, sample size, design, and status.
Request an evidence briefing